32.31
-2.11 (-6.13%)
| Penutupan Terdahulu | 34.42 |
| Jumlah Dagangan | 75,671 |
| Harga / Jualan (P/S) | 2.90 |
| Harga / Buku (P/B) | 2.27 |
| Julat 52 Minggu |
| Margin Keuntungan | -1.46% |
| Margin Operasi (TTM) | -31.74% |
| EPS Cair (TTM) | -0.190 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 20.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 5.87% |
| Nisbah Semasa (MRQ) | 9.37 |
| Aliran Tunai Operasi (OCF TTM) | 65.67 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 44.64 M |
| Pulangan Atas Aset (ROA TTM) | -1.80% |
| Pulangan Atas Ekuiti (ROE TTM) | -1.20% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | Castle Biosciences, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -3.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | NA |
| AI Insight | NA |
| Purata | -0.88 |
|
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.98% |
| % Dimiliki oleh Institusi | 93.02% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Summit Partners Public Asset Management, Llc | 30 Jun 2026 | 824,872 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| MAETZOLD DEREK J | - | 36.65 | -14,496 | -531,278 |
| Jumlah Keseluruhan Kuantiti Bersih | -14,496 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -531,278 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 36.65 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| MAETZOLD DEREK J | Pegawai | 05 Oct 2026 | Jual automatik (-) | 8,580 | 36.65 | 314,457 |
| MAETZOLD DEREK J | Pegawai | 05 Oct 2026 | Jual automatik (-) | 5,916 | 36.65 | 216,821 |
| MAETZOLD DEREK J | Pegawai | 05 Oct 2026 | Pelaksanaan pilihan | 8,165 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |